» Articles » PMID: 19421774

Extraconal Orbital Tumors in Children--a Spectrum

Overview
Journal Virchows Arch
Date 2009 May 8
PMID 19421774
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Orbital masses in children are uncommon but extremely challenging problems for clinicians and pathologists due to their critical location and availability of limited diagnostic material. We analyzed 47 specimens comprising biopsies, excision specimens, and FNAC of extraconal pediatric orbital masses (excluding retinoblastoma) accessioned in the pathology department over 5 years in a tertiary referral cancer center. Immunohistochemistry (IHC-74%) and molecular methods (one case) were done where necessary. The chief presenting symptom was proptosis in 55.3% patients and radiologically 53.8% malignant tumors showed extraorbital extension. A diagnostic algorithm was formulated to assess which cases needed pathology evaluation. Malignant round cell tumors (76.6%), chiefly embryonal rhabdomyosarcoma (51%), benign spindle cell neoplasms, and infectious lesions (tuberculosis, fungal infections), were seen. Of the malignant tumors, those confined to the orbit achieved good treatment response and had an event-free follow-up while those with extraorbital spread had poor outcome. Pediatric orbital masses range from completely treatable infectious lesions, surgically resectable benign neoplasms to aggressive malignancies requiring chemotherapy and radiotherapy. Pathologists play a key role in distinguishing these on small biopsy material and expediating accurate treatment thus saving the vision or life of a patient.

Citing Articles

Receptor tyrosine kinase gene expression profiling of orbital rhabdomyosarcoma unveils MET as a potential biomarker and therapeutic target.

Chauhan S, Sen S, Irshad K, Kashyap S, Pushker N, Meel R Hum Cell. 2023; 37(1):297-309.

PMID: 37914903 DOI: 10.1007/s13577-023-00993-5.


Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Various Orbital Malignancies.

Natarajan A, Chandra P, Purandare N, Agrawal A, Shah S, Puranik A Indian J Nucl Med. 2018; 33(2):118-124.

PMID: 29643671 PMC: 5883428. DOI: 10.4103/ijnm.IJNM_135_17.


Orbital rhabdomyosarcomas: A review.

Jurdy L, Merks J, Pieters B, Mourits M, Kloos R, Strackee S Saudi J Ophthalmol. 2013; 27(3):167-75.

PMID: 24227982 PMC: 3770217. DOI: 10.1016/j.sjopt.2013.06.004.


Visual function alterations in orbital tumors and factors predicting visual outcome after surgery.

Singh D, Pushker N, Bajaj M, Saxena R, Sharma S, Ghose S Eye (Lond). 2011; 26(3):448-53.

PMID: 22157916 PMC: 3298991. DOI: 10.1038/eye.2011.308.

References
1.
Maurer H, Beltangady M, Gehan E, Crist W, Hammond D, Hays D . The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988; 61(2):209-20. DOI: 10.1002/1097-0142(19880115)61:2<209::aid-cncr2820610202>3.0.co;2-l. View

2.
Conneely M, Mafee M . Orbital rhabdomyosarcoma and simulating lesions. Neuroimaging Clin N Am. 2005; 15(1):121-36. DOI: 10.1016/j.nic.2005.02.006. View

3.
Shields C, Shields J, Honavar S, Demirci H . Primary ophthalmic rhabdomyosarcoma in 33 patients. Trans Am Ophthalmol Soc. 2002; 99:133-42; discussion 142-3. PMC: 1359004. View

4.
Crist W, ANDERSON J, Meza J, Fryer C, RANEY R, RUYMANN F . Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001; 19(12):3091-102. DOI: 10.1200/JCO.2001.19.12.3091. View

5.
Sebire N, Malone M . Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol. 2003; 56(6):412-6. PMC: 1769965. DOI: 10.1136/jcp.56.6.412. View